SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

🎯 Drug Targets

Browse 12 drug targets with druggability analysis, composite scores, and clinical context

12
Targets
0
High Druggability
0.55
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 12Low: 0Unknown: 0
Avg druggability score: 0.521
Clinical Pipeline
Approved: 7Phase III: 1Phase II: 2Phase I: 2Preclinical: 0
Total compounds: 21 · Approved: 11
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Receptor (11) Transcription Factor (11) Ligand (10) Epigenetic Regulator (8) Transporter (8) Kinase (7) Other (4) Protease (4) Chaperone (4)
Druggability All Druggability Low (97) Medium (56) Undruggable (19) High (10) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=enzyme, druggability=Medium — 12 results
PARP1 Poly [ADP-ribose] polymerase 1 Approved
Enzyme Medium Druggability
Score
0.66
Drug.
0.62
Safety
0.60
Drugs
3
Hyps
6
Papers
32
Competitive inhibitors of PARP1 enzymatic activity blocking DNA repair
TH Tyrosine hydroxylase Approved
Enzyme Medium Druggability
Score
0.65
Drug.
0.54
Safety
0.40
Drugs
2
Hyps
157
Papers
0
Enzyme replacement therapy via L-DOPA supplementation to bypass reduced TH activity
CGAS Cyclic GMP-AMP synthase Phase III
Enzyme Medium Druggability
Score
0.63
Drug.
0.47
Safety
0.60
Drugs
1
Hyps
3
Papers
22
Small molecule inhibitor of cyclic dinucleotide synthesis
TGM2 Protein-glutamine gamma-glutamyltransferase 2 Phase II
Enzyme Medium Druggability
Score
0.59
Drug.
0.49
Safety
0.50
Drugs
2
Hyps
1
Papers
32
Small molecule inhibitors of transglutaminase enzymatic activity
CD38 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Approved
Enzyme Medium Druggability
Score
0.59
Drug.
0.61
Safety
0.50
Drugs
2
Hyps
2
Papers
22
Monoclonal antibody targeting or small molecule inhibitor of NAD+ consuming activity
FKBP5 FKBP prolyl isomerase 5 Phase I
Enzyme Medium Druggability
Score
0.59
Drug.
0.47
Safety
0.60
Drugs
2
Hyps
4
Papers
14
Small molecule inhibitor of prolyl isomerase activity and HSP90 co-chaperone function
ALOX5 5-lipoxygenase Approved
Enzyme Medium Druggability
Score
0.56
Drug.
0.49
Safety
0.70
Drugs
1
Hyps
1
Papers
31
Small molecule inhibitors blocking leukotriene synthesis
VCP Valosin containing protein Phase I
Enzyme Medium Druggability
Score
0.54
Drug.
0.50
Safety
0.30
Drugs
1
Hyps
2
Papers
0
Small molecule inhibitors of VCP ATPase activity affecting protein quality control
CYP46A1 Cytochrome P450 Family 46 Subfamily A Member 1 Approved
Enzyme Medium Druggability
Score
0.51
Drug.
0.51
Safety
0.70
Drugs
1
Hyps
4
Papers
0
Small molecule activator of cholesterol 24-hydroxylase enhancing brain cholesterol turnover
SMPD1 Sphingomyelin phosphodiesterase 1 Approved
Enzyme Medium Druggability
Score
0.51
Drug.
0.47
Safety
0.40
Drugs
1
Hyps
1
Papers
0
Small molecule inhibitor or modulator of sphingomyelinase activity
AADC Aromatic L-amino acid decarboxylase Approved
Enzyme Medium Druggability
Score
0.38
Drug.
0.50
Safety
0.40
Drugs
1
Hyps
1
Papers
0
Small molecule inhibitor preventing peripheral conversion of levodopa to dopamine
SIRT3 NAD-dependent deacetylase sirtuin-3, mitochondrial Phase II
Enzyme Medium Druggability
Score
0.38
Drug.
0.61
Safety
0.75
Drugs
4
Hyps
2
Papers
10
Enzyme activation — enhancing SIRT3 deacetylase activity restores mitochondrial protein function and reduces oxidative stress
Exchange | Dashboard